Scott A. Boerner

3.0k total citations
40 papers, 2.2k citations indexed

About

Scott A. Boerner is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Scott A. Boerner has authored 40 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 22 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Scott A. Boerner's work include PARP inhibition in cancer therapy (8 papers), DNA Repair Mechanisms (6 papers) and Cancer therapeutics and mechanisms (6 papers). Scott A. Boerner is often cited by papers focused on PARP inhibition in cancer therapy (8 papers), DNA Repair Mechanisms (6 papers) and Cancer therapeutics and mechanisms (6 papers). Scott A. Boerner collaborates with scholars based in United States, United Kingdom and Canada. Scott A. Boerner's co-authors include Patricia LoRusso, Joseph P. Eder, George F. Vande Woude, Karen H. Martin, J. Thomas Parsons, Scott H. Kaufmann, Jill K. Slack, Ding Wang, James D. Winkler and Keith C. Bible and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Scott A. Boerner

40 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott A. Boerner United States	23	1.2k	852	337	334	278	40	2.2k
Graham F. Barnard United States	25	1.6k 1.3×	1.5k 1.7×	302 0.9×	756 2.3×	308 1.1×	63	3.0k
Ling Geng United States	28	1.9k 1.6×	981 1.2×	539 1.6×	866 2.6×	138 0.5×	50	3.1k
Dean Wilkie United States	12	1.2k 1.0×	705 0.8×	376 1.1×	560 1.7×	620 2.2×	16	2.5k
Darren R. Carpizo United States	27	1.5k 1.2×	1.4k 1.6×	325 1.0×	715 2.1×	367 1.3×	80	3.0k
Arianna Giacomini Italy	25	1.2k 1.0×	407 0.5×	224 0.7×	356 1.1×	254 0.9×	67	2.0k
Li Zhou China	32	1.5k 1.3×	905 1.1×	297 0.9×	1.0k 3.1×	293 1.1×	118	2.7k
Richard Sesboüé France	27	1.0k 0.9×	1.2k 1.4×	806 2.4×	570 1.7×	144 0.5×	91	2.7k
Giulio Francia United States	31	1.5k 1.3×	1.5k 1.8×	540 1.6×	849 2.5×	197 0.7×	69	3.2k
Frank Hilberg Austria	28	2.0k 1.6×	1.1k 1.3×	1.2k 3.6×	497 1.5×	257 0.9×	57	4.0k
László Kopper Hungary	26	821 0.7×	512 0.6×	293 0.9×	343 1.0×	63 0.2×	81	1.6k

Countries citing papers authored by Scott A. Boerner

Since Specialization

Citations

This map shows the geographic impact of Scott A. Boerner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Boerner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Boerner more than expected).

Fields of papers citing papers by Scott A. Boerner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Boerner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Boerner. The network helps show where Scott A. Boerner may publish in the future.

Co-authorship network of co-authors of Scott A. Boerner

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Boerner. A scholar is included among the top collaborators of Scott A. Boerner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Boerner. Scott A. Boerner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rathmell, W. Kimryn, Geoffrey I. Shapiro, Naoko Takebe, et al.. (2024). A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Research Communications. 4(7). 1793–1801. 6 indexed citations

Rathmell, W. Kimryn, Geoffrey I. Shapiro, Jordi Rodón, et al.. (2023). A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.. Journal of Clinical Oncology. 41(16_suppl). 3104–3104. 2 indexed citations

Cecchini, Michael, Zenta Walther, Wei Wei, et al.. (2023). NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications. 3(6). 1113–1117. 2 indexed citations

Pilat, Mary Jo, Derek Shyr, Yu Shyr, et al.. (2023). Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer Research Communications. 3(2). 192–201. 18 indexed citations

Shah, Ritu, Scott A. Boerner, Jing Li, et al.. (2022). Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.. Journal of Clinical Oncology. 40(16_suppl). 2035–2035. 5 indexed citations

Sullivan, Ryan J., Patricia LoRusso, Scott A. Boerner, & Reinhard Dummer. (2015). Achievements and Challenges of Molecular Targeted Therapy in Melanoma. American Society of Clinical Oncology Educational Book. 177–186. 36 indexed citations

Boerner, Julie L., Kelly L. Mueller, Lisa Polin, et al.. (2015). Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer. PLoS ONE. 10(3). e0119614–e0119614. 22 indexed citations

LoRusso, Patricia, Renzo Canetta, John A. Wagner, et al.. (2012). Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop. Clinical Cancer Research. 18(22). 6101–6109. 42 indexed citations

LoRusso, Patricia, Lowell E. Schnipper, David J. Stewart, et al.. (2010). Translating Clinical Trials into Meaningful Outcomes. Clinical Cancer Research. 16(24). 5951–5955. 16 indexed citations

10.

LoRusso, Patricia, Scott A. Boerner, & Lesley Seymour. (2010). An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics. Clinical Cancer Research. 16(6). 1710–1718. 67 indexed citations

11.

LoRusso, Patricia & Scott A. Boerner. (2010). The Role of Phosphoinositide 3-Kinase in Breast Cancer: An Overview. Clinical Breast Cancer. 10. S56–S58. 1 indexed citations

12.

LoRusso, Patricia, Shirish M. Gadgeel, Antoinette Wozniak, et al.. (2008). Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Investigational New Drugs. 26(2). 159–167. 54 indexed citations

13.

Gonçalves, Priscila, et al.. (2008). Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies. Investigational New Drugs. 26(4). 347–354. 10 indexed citations

14.

Wang, Ding, Scott A. Boerner, James D. Winkler, & Patricia LoRusso. (2006). Clinical experience of MEK inhibitors in cancer therapy. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1773(8). 1248–1255. 136 indexed citations

15.

Dalton, Pamela, Shirley L. MacDonald, & Scott A. Boerner. (2006). Acetic Acid Recovery of Gynecologic Liquid-Based Samples of Apparent Low Squamous Cellularity. Journal of Lower Genital Tract Disease. 10(4). 273–274. 1 indexed citations

16.

Chianese‐Bullock, Kimberly A., Elizabeth M. H. Woodson, Huimin Tao, et al.. (2005). Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2. Journal of Immunotherapy. 28(4). 412–419. 32 indexed citations

17.

Adjei, Alex A., Joel M. Reid, Charles Erlichman, et al.. (2002). A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer. Investigational New Drugs. 20(3). 297–304. 6 indexed citations

18.

Kottke, Timothy, April L. Blajeski, X. Wei Meng, et al.. (2002). Lack of Correlation between Caspase Activation and Caspase Activity Assays in Paclitaxel-treated MCF-7 Breast Cancer Cells. Journal of Biological Chemistry. 277(1). 804–815. 64 indexed citations

19.

Martin, Karen H., Scott A. Boerner, & J. Thomas Parsons. (2002). Regulation of focal adhesion targeting and inhibitory functions of the FAK related protein FRNK using a novel estrogen receptor “switch”. Cell Motility and the Cytoskeleton. 51(2). 76–88. 14 indexed citations

20.

Bible, Keith C., Scott A. Boerner, Keiren Kirkland, et al.. (2000). Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.. PubMed. 6(2). 661–70. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact